Source:http://linkedlifedata.com/resource/pubmed/id/19707350
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2009-8-26
|
| pubmed:abstractText |
We report our single center experience with the use of basiliximab, a chimeric monoclonal antibody directed against the alpha chain of the interleukin-2 (IL-2) receptor (CD25), in combination with a steroid- and tacrolimus-based regimen in adult to adult living-related liver transplantation (ALRLT). Sixty consecutive ALRLTs were analyzed. All patients received two 20-mg doses of basiliximab (days 0 and 4 after transplantation) followed by tacrolimus (0.15 mg/kg/day; 10-15 ng/mL target trough levels) and a dose regimen of steroids (starting with 20 mg iv, switched to po as soon as the patient was able to eat, and weaned off within 1-2 months). Follow-up ranged from 6 to 1699.4 days after transplantation (mean 517.5 days, SD +/- 413.4; median 424 days). Of the recipients, 95% remained rejection-free during follow-up, with an actuarial rejection-free probability of 96.61% within 3 months. Three patients had episodes of biopsy-proven acute cellular rejection (ACR). Actuarial patient and graft survival rates at 3 years were 82.09% and 75.61%. Six patients (10%) experienced sepsis. There was no evidence of cytomegalovirus infections or side-effects related to the basiliximab. We found zero de novo malignancy, although we observed 5 patients with metastatic spread of their primary malignancy during the follow-up. Basiliximab in association with tacrolimus and steroids is effective in reducing episodes of ACR and increasing ACR-free survival after ALRLT.
|
| pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-10075594,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-10648573,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-11003347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-11602853,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-11985487,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-12689974,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-15385809,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-15964369,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-16182753,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-16182762,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-16757278,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-17093248,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19707350-9652559
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:status |
PubMed-not-MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1177-5475
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
69-73
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Role of basiliximab in the prevention of acute cellular rejection in adult to adult living-related liver transplantation: a single center experience.
|
| pubmed:affiliation |
Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione (IsMeTT), Italy, Palermo, Italy; University of Pittsburgh Medical Center (UPMC) Italy, Palermo, Italy.
|
| pubmed:publicationType |
Journal Article
|